Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.59
CLSN's Cash to Debt is ranked lower than
71% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CLSN: 2.59 )
Ranked among companies with meaningful Cash to Debt only.
CLSN' s Cash to Debt Range Over the Past 10 Years
Min: 0.45  Med: 31.14 Max: No Debt
Current: 2.59
Equity to Asset 0.35
CLSN's Equity to Asset is ranked lower than
82% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. CLSN: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
CLSN' s Equity to Asset Range Over the Past 10 Years
Min: -1.05  Med: 0.59 Max: 0.97
Current: 0.35
-1.05
0.97
F-Score: 3
Z-Score: -7.89
M-Score: -3.36
WACC vs ROIC
19.21%
-292.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3922.60
CLSN's Operating margin (%) is ranked lower than
87% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. CLSN: -3922.60 )
Ranked among companies with meaningful Operating margin (%) only.
CLSN' s Operating margin (%) Range Over the Past 10 Years
Min: -4943  Med: -806.46 Max: -75.32
Current: -3922.6
-4943
-75.32
Net-margin (%) -4234.40
CLSN's Net-margin (%) is ranked lower than
88% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. CLSN: -4234.40 )
Ranked among companies with meaningful Net-margin (%) only.
CLSN' s Net-margin (%) Range Over the Past 10 Years
Min: -5098.8  Med: -816.30 Max: -67.41
Current: -4234.4
-5098.8
-67.41
ROE (%) -90.80
CLSN's ROE (%) is ranked lower than
80% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CLSN: -90.80 )
Ranked among companies with meaningful ROE (%) only.
CLSN' s ROE (%) Range Over the Past 10 Years
Min: -6771.43  Med: -107.47 Max: 257.55
Current: -90.8
-6771.43
257.55
ROA (%) -39.76
CLSN's ROA (%) is ranked lower than
63% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CLSN: -39.76 )
Ranked among companies with meaningful ROA (%) only.
CLSN' s ROA (%) Range Over the Past 10 Years
Min: -217.17  Med: -49.04 Max: 121.96
Current: -39.76
-217.17
121.96
ROC (Joel Greenblatt) (%) -2131.89
CLSN's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CLSN: -2131.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLSN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4101.97  Med: -647.94 Max: -115.63
Current: -2131.89
-4101.97
-115.63
Revenue Growth (3Y)(%) -60.30
CLSN's Revenue Growth (3Y)(%) is ranked lower than
87% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CLSN: -60.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CLSN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 5.3
Current: -60.3
0
5.3
EBITDA Growth (3Y)(%) -35.70
CLSN's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CLSN: -35.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CLSN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.6  Med: -4.05 Max: 39.1
Current: -35.7
-57.6
39.1
EPS Growth (3Y)(%) -34.90
CLSN's EPS Growth (3Y)(%) is ranked lower than
83% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CLSN: -34.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CLSN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.2  Med: -2.15 Max: 28.8
Current: -34.9
-48.2
28.8
» CLSN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CLSN Guru Trades in Q2 2015

Jim Simons 71,210 sh (+71.03%)
Chuck Royce 213,159 sh (unchged)
» More
Q3 2015

CLSN Guru Trades in Q3 2015

Jim Simons Sold Out
Chuck Royce 167,379 sh (-21.48%)
» More
Q4 2015

CLSN Guru Trades in Q4 2015

Jim Simons 25,648 sh (New)
Chuck Royce Sold Out
» More
Q1 2016

CLSN Guru Trades in Q1 2016

Jim Simons 27,648 sh (+7.80%)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:LSE:IMM, ROCO:4186, XPAR:ALQGC, ASX:AHZ, OSTO:BINV, OTCPK:RGRX » details
Traded in other countries:CBOB.Germany,
Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.

Celsion Corp is a Delaware corporation incorporated in 1982. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.

Ratios

vs
industry
vs
history
P/B 2.18
CLSN's P/B is ranked higher than
69% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CLSN: 2.18 )
Ranked among companies with meaningful P/B only.
CLSN' s P/B Range Over the Past 10 Years
Min: 1.25  Med: 2.25 Max: 167.59
Current: 2.18
1.25
167.59
P/S 64.07
CLSN's P/S is ranked lower than
79% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. CLSN: 64.07 )
Ranked among companies with meaningful P/S only.
CLSN' s P/S Range Over the Past 10 Years
Min: 2.22  Med: 19.66 Max: 585.38
Current: 64.07
2.22
585.38
Current Ratio 1.54
CLSN's Current Ratio is ranked lower than
82% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CLSN: 1.54 )
Ranked among companies with meaningful Current Ratio only.
CLSN' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 4.47 Max: 104.65
Current: 1.54
0.3
104.65
Quick Ratio 1.54
CLSN's Quick Ratio is ranked lower than
78% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CLSN: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
CLSN' s Quick Ratio Range Over the Past 10 Years
Min: 0.3  Med: 3.86 Max: 104.65
Current: 1.54
0.3
104.65
Days Sales Outstanding 19.71
CLSN's Days Sales Outstanding is ranked higher than
82% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. CLSN: 19.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
CLSN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.21  Med: 153.30 Max: 2190
Current: 19.71
21.21
2190

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.28
CLSN's Price/Median PS Value is ranked lower than
89% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CLSN: 3.28 )
Ranked among companies with meaningful Price/Median PS Value only.
CLSN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 4.73 Max: 4324.13
Current: 3.28
0.14
4324.13
Earnings Yield (Greenblatt) (%) -82.14
CLSN's Earnings Yield (Greenblatt) (%) is ranked lower than
90% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CLSN: -82.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLSN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -82.14  Med: 693.60 Max: 845.7
Current: -82.14
-82.14
845.7

More Statistics

Revenue (TTM) (Mil) $0.50
EPS (TTM) $ -0.94
Beta2.35
Short Percentage of Float3.40%
52-Week Range $1.04 - 2.78
Shares Outstanding (Mil)23.44

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 0 0
EPS ($) -0.81 -0.64 -0.79
EPS without NRI ($) -0.81 -0.64 -0.79
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 

More From Other Websites
CELSION CORP Financials May 24 2016
Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting May 24 2016
Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting May 24 2016
Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update May 16 2016
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 16 2016
Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update May 16 2016
Should You Buy Celsion (CLSN) Ahead of Earnings? May 09 2016
Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16,... May 09 2016
Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16,... May 09 2016
Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study May 02 2016
Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study May 02 2016
Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China Apr 26 2016
Celsion Corporation Announces Enrollment of First Patient in the OPTIMA Study in China Apr 26 2016
Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1... Apr 19 2016
Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1... Apr 19 2016
Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12... Apr 12 2016
Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12... Apr 12 2016
Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 06 2016
Celsion Corp. :CLSN-US: Earnings Analysis: 2015 By the Numbers Apr 06 2016
Edited Transcript of CLSN earnings conference call or presentation 30-Mar-16 3:00pm GMT Apr 01 2016
Celsion Corp Earnings Call scheduled for 11:00 am ET today Mar 30 2016
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 30 2016
Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update Mar 30 2016
Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update Mar 30 2016
Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30,... Mar 23 2016
Celsion Corporation to Hold Year-End 2015 Financial Results Conference Call on Wednesday, March 30,... Mar 23 2016
Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with... Mar 16 2016
[$$] Cancer Therapy May See Major Shift Mar 15 2016
Celsion Corporation Announces Launch of the OPTIMA Study in China Mar 07 2016
Celsion Corporation Announces Issuance of Key U.S. Patent Covering its Novel TheraSilence™ RNA... Mar 01 2016
Celsion (CLSN) Provides Pipeline Update, GEN-1 in Focus Feb 15 2016
Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in... Jan 07 2016
Celsion Announces Appointment of Two New Members to Its Board of Directors Dec 17 2015
Celsion Receives CFDA Approval to Conduct the OPTIMA Study in China Dec 16 2015
Celsion Announces Presentation of DIGNITY Phase I/II ThermoDox® Data at the 2015 San Antonio Breast... Dec 14 2015
Celsion Corporation to Present at the LD Micro Main Event Investor Conference Nov 24 2015
Celsion Corporation Announces Dual Listing on the Tel Aviv Stock Exchange Nov 11 2015
Celsion Corporation Reports Third Quarter 2015 Financial Results and Provides Business Update Nov 05 2015
Celsion Corporation Names Edwin De Wit, M.D. as Senior Vice President and Head of Medical, Europe Nov 03 2015
Celsion Presents Data on ThermoDox® plus Optimized RFA in Intermediate HCC at the 2nd Asian... Nov 02 2015
Celsion Corporation to Hold Third Quarter 2015 Financial Results Conference Call on Thursday,... Oct 29 2015
Celsion Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with... Oct 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)